These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 10168093)

  • 21. Economic considerations in the prescribing of third-generation antidepressants.
    Montgomery S; Doyle JJ; Stern L; McBurney CR
    Pharmacoeconomics; 2005; 23(5):477-91. PubMed ID: 15896099
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased use of antidepressants in Canada: 1981-2000.
    Hemels ME; Koren G; Einarson TR
    Ann Pharmacother; 2002 Sep; 36(9):1375-9. PubMed ID: 12196054
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Liability in prescribing choice: the example of the antidepressants.
    Beerworth EE; Tiller JW
    Aust N Z J Psychiatry; 1998 Aug; 32(4):560-6. PubMed ID: 9711371
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modelling the cost effectiveness of antidepressant treatment in primary care.
    Revicki DA; Brown RE; Palmer W; Bakish D; Rosser WW; Anton SF; Feeny D
    Pharmacoeconomics; 1995 Dec; 8(6):524-40. PubMed ID: 10160081
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Antidepressants consumption in the global population in France].
    Olié JP; Elomari F; Spadone C; Lépine JP
    Encephale; 2002; 28(5 Pt 1):411-7. PubMed ID: 12386542
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economic impact of non-persistence to antidepressant therapy in the Quebec community-dwelling elderly population.
    Tournier M; Moride Y; Crott R; du Fort GG; Ducruet T
    J Affect Disord; 2009 May; 115(1-2):160-6. PubMed ID: 18694602
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Utilization, price, and spending trends for antidepressants in the US Medicaid Program.
    Chen Y; Kelton CM; Jing Y; Guo JJ; Li X; Patel NC
    Res Social Adm Pharm; 2008 Sep; 4(3):244-57. PubMed ID: 18794035
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Are psychological treatments for depression in primary care cost-effective?
    Bosmans JE; van Schaik DJ; de Bruijne MC; van Hout HP; van Marwijk HW; van Tulder MW; Stalman WA
    J Ment Health Policy Econ; 2008 Mar; 11(1):3-15. PubMed ID: 18424872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mental health care system optimization from a health-economics perspective: where to sow and where to reap?
    Lokkerbol J; Weehuizen R; Mavranezouli I; Mihalopoulos C; Smit F
    J Ment Health Policy Econ; 2014 Jun; 17(2):51-60. PubMed ID: 25153093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The cost of depression in the elderly. Effects of drug therapy.
    Hughes D; Morris S; McGuire A
    Drugs Aging; 1997 Jan; 10(1):59-68. PubMed ID: 9111708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evidence of cost-effective treatments for depression: a systematic review.
    Barrett B; Byford S; Knapp M
    J Affect Disord; 2005 Jan; 84(1):1-13. PubMed ID: 15620380
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Who bears the cost of antidepressants in Australia?
    Alchin TM; Tranby HW
    Med J Aust; 1994 Nov; 161(9):547-9. PubMed ID: 7968757
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Choice of generic versus brand-name antidepressants in a regulated prescription drug market: evidence from Taiwan.
    Liu YM; Ou HT; Yang YK
    J Ment Health Policy Econ; 2014 Dec; 17(4):163-72. PubMed ID: 25599280
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Choosing appropriate antidepressant therapy in the elderly. A risk-benefit assessment of available agents.
    Flint AJ
    Drugs Aging; 1998 Oct; 13(4):269-80. PubMed ID: 9805208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Determinants of antidepressant medication prescribing in elderly residents of aged care homes in Australia: a retrospective study.
    Nishtala PS; McLachlan AJ; Bell JS; Chen TF
    Am J Geriatr Pharmacother; 2009 Aug; 7(4):210-9. PubMed ID: 19766953
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antidepressant utilization in primary care in a Spanish region: impact of generic and reference-based pricing policy (2000-2004).
    Ubeda A; Cardo E; Sellés N; Broseta R; Trillo JL; Fernández-Llimós F
    Soc Psychiatry Psychiatr Epidemiol; 2007 Mar; 42(3):181-8. PubMed ID: 17235443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness comparisons between antidepressant treatments in depression: evidence from database analyses and prospective studies.
    Pan YJ; Knapp M; McCrone P
    J Affect Disord; 2012 Jul; 139(2):113-25. PubMed ID: 21851987
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness comparisons using "real world" randomized trials: the case of new antidepressant drugs.
    Simon G; Wagner E; Vonkorff M
    J Clin Epidemiol; 1995 Mar; 48(3):363-73. PubMed ID: 7897458
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost analysis of registered brands of oral antidepressant drugs in Pakistan: a descriptive analysis.
    Kamran S; Saqlain M; Khan Z; Mahmood S; Ali H; Ahmad N; Shah KU
    Expert Rev Pharmacoecon Outcomes Res; 2020 Oct; 20(5):473-479. PubMed ID: 31498710
    [No Abstract]   [Full Text] [Related]  

  • 40. Therapeutic drug monitoring for antidepressant drug treatment.
    Ostad Haji E; Hiemke C; Pfuhlmann B
    Curr Pharm Des; 2012; 18(36):5818-27. PubMed ID: 22681162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.